View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAptahem 配当と自社株買い配当金 基準チェック /06Aptahem配当金を支払った記録がありません。主要情報n/a配当利回り-73.4%バイバック利回り総株主利回り-73.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026お知らせ • Mar 27Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million. Security Name: Shares Security Type: Common Stock Securities Offered: 20,972,162 Price\Range: SEK 0.66 Transaction Features: Rights OfferingBoard Change • Mar 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).お知らせ • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025お知らせ • Sep 02Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million. Security Name: Shares Security Type: Common Stock Securities Offered: 15,346,296 Price\Range: SEK 1.62 Transaction Features: Rights OfferingNew Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (205% increase in shares outstanding). Revenue is less than US$1m (kr3.7m revenue, or US$388k). Market cap is less than US$10m (€2.73m market cap, or US$3.19m).Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).お知らせ • Aug 28Aptahem AB (publ) Announces Submission of Application for FDA's Commissioner's National Priority Voucher Pilot ProgramAptahem AB (publ) announced that the company has submitted an application for participation in the U.S. Food and Drug Administration's (FDA) Commissioner's National Priority Voucher (CNPV) Pilot Program - "Accelerated Drug Review for Companies Supporting U.S. National Interests." The application is made as a next step after Aptahem's previous application to FDA PreCheck on August 13, 2025. It complements the company's application to FDA PreCheck and strengthens the U.S.-focused regulatory strategy. CNPV is a new pilot program where the FDA, for a limited number of companies, can award a "voucher" that provides significantly shortened regulatory review processing times - from normally around 10-12 months to around 1-2 months - while maintaining applicable safety and efficacy requirements. The selection is directed at development programs that are in line with US national health priorities (e.g., high unmet medical needs, innovation level, crisis management, onshoring, and supply chain robustness). In the first round of the pilot year, a maximum of five participants are intended to be selected. To qualify, it is required, among other things, that the manufacturing part and proposed labeling are submitted at least 60 days before the final application and that the company can maintain a close dialogue with the FDA's cross-functional review team.お知らせ • Aug 21Aptahem Files Provisional Patent Application in Usa for New Indications for Apta-1Aptahem AB (publ) announced that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1. These new insights are based on the detailed evaluation of data generated from Apta-1 by the Company's Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified entirely new indications for the Company's lead RNA aptamer, Apta-1. These discoveries are now protected by a provisional patent application in the United States, further strengthening Apta-1's position as a first-in-class, innovative therapy option. Some of the identified indications include: Neurodegenerative diseases: Apta-1 blocks interactions of Amyloid-b and tau, with the potential to slow progression in Alzheimer's, Parkinson's, frontotemporal dementia, and Huntington's disease. Viral infections: Effective against HSV, CMV, Dengue, Zika, SARS-CoV-2, MERS, HIV, and HPV by preventing viral cell entry. Cancer and metastasis: Inhibits growth factors, slowing angiogenesis and tumor cell spread in aggressive cancers such as breast cancer, melanoma, and glioblastoma. Fibrotic diseases and infectious conditions: interesting indications for idiopathic pulmonary fibrosis, liver and kidney fibrosis, as well as in certain infectious diseases. Dr. Jedlina's evaluation of the study results shows that Apta-1 has the potential to stop disease-driving mechanisms at multiple levels - from protein aggregation and pathogen entry to tissue damage and fibrosis - making Apta-1 a potential game-changer in these indication areas.お知らせ • Aug 16Aptahem AB (publ) Applies to FDA Precheck Program - Strategic Step Toward Faster, Higher-Quality Drug ManufacturingAptahem AB (publ) is strengthening its position as a leader in RNA-based therapeutics by applying to the FDA PreCheck Program, the agency's new initiative to accelerate and streamline inspections of drug manufacturing. The program is reserved for companies with a proven track record of high-quality, GMP-compliant operations, offering prioritized inspections and regulatory transparency. For Aptahem, participation means:Faster regulatory pathway for production of Apta-1, its breakthrough RNA aptamer for severe inflammatory conditions. Enhanced confidence from partners and investors, demonstrating the company's commitment to top-tier quality and innovation. Clear quality milestone reducing risks and timelines, supporting future clinical and commercial expansion.お知らせ • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).お知らせ • May 08Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Mar 14Aptahem AB (publ) Presents Plan for Upcoming Patient StudyAptahem AB (publ) announced a summary for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed as an open, single arm phase 2 study to evaluate the efficacy and safety of Apta-1, an innovative immunomodulatory and antithrombotic drug candidate, in patients with acute urogenital andrenal conditions. The study will be perform as a Proof-of-Concept study in adult patients diagnosed with various types of acute urogenital disorders including acute kidney disorders. Within these disorders, there are several indications with orphan status, an area where Aptahem sees great potential for Apta-1 based on its unique therapeutic profile. To maximize the opportunities to create value from Apta-1's broad treatment potential, the study is planned to be conducted as a "basket trial", where several acute medical conditions within the relevant patient group are investigated in parallel. The study's primary objectives include biomarkers for hematology, organ function, inflammation, tissue degradation, and reduction of pathogens such as viruses and bacteria. The goal is to demonstrate both therapeutic efficacy and safety. More detailed information about the study will be published in the near future.Reported Earnings • Feb 20Full year 2024 earnings released: kr0.69 loss per share (vs kr5.79 loss in FY 2023)Full year 2024 results: kr0.69 loss per share (improved from kr5.79 loss in FY 2023). Net loss: kr8.57m (loss narrowed 23% from FY 2023).お知らせ • Feb 18+ 1 more updateAptahem AB (publ) to Report Q1, 2025 Results on May 28, 2025Aptahem AB (publ) announced that they will report Q1, 2025 results on May 28, 2025お知らせ • Jan 16Aptahem AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025Aptahem AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Dec 03Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.18m (loss narrowed 26% from 3Q 2023).Board Change • Dec 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 31Aptahem AB (publ) to Report Q3, 2024 Results on Nov 29, 2024Aptahem AB (publ) announced that they will report Q3, 2024 results on Nov 29, 2024お知らせ • Sep 02Aptahem AB (Publ) Announces Completion of Double-Blind Randomised Placebo-Controlled Phase 1 StudyAptahem AB (publ) announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. The analyses revealed that one individual had elevated inflammatory values prior to dosing. In this case, Apta-1 dosing was associated with rapid reduction of inflammatory parameters, with the first signs of normalisation seen already within 4 hours of dosing and further reduction at 6 hours to be completely reduced at the next measurement point at 24 hours. This suggests that Apta-1 could counteract inflammatory responses in individuals with ongoing inflammation. The latter observations are consistent with preclinical data and the proposed mechanism of action showing that Apta-1 protects against acute inflammation. This has been replicated in several independent models and reinforces the belief that Apta-1 can be developed into an effective drug against life-threatening inflammatory disease. Strengthened by these findings, a confirmatory Phase 2 clinical trial in patients with acute inflammatory disease is now being planned in consultation with the company's expert advisors.Reported Earnings • Sep 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr2.63m (loss narrowed 3.7% from 2Q 2023).お知らせ • Aug 01Aptahem AB (publ) to Report Q2, 2024 Results on Aug 30, 2024Aptahem AB (publ) announced that they will report Q2, 2024 results on Aug 30, 2024Board Change • Jul 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 28Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been FinalizedAptahem AB (publ) announced that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities. The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study of Apta-1 highlighted some clinical markers which are important for understanding the mechanism of action and to support upcoming patient studies. The significance of these findings are being further investigated aided by pre-clinical studies.Board Change • Jun 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Jan Nilsson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 94Vの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 94Vの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Aptahem 配当利回り対市場94V 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (94V)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.2%アナリスト予想 (94V) (最長3年)n/a注目すべき配当: 94Vは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 94Vは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 94Vの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 94Vが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/02 09:51終値2026/03/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aptahem AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026
お知らせ • Mar 27Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million. Security Name: Shares Security Type: Common Stock Securities Offered: 20,972,162 Price\Range: SEK 0.66 Transaction Features: Rights Offering
Board Change • Mar 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).
お知らせ • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025
お知らせ • Sep 02Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million. Security Name: Shares Security Type: Common Stock Securities Offered: 15,346,296 Price\Range: SEK 1.62 Transaction Features: Rights Offering
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (205% increase in shares outstanding). Revenue is less than US$1m (kr3.7m revenue, or US$388k). Market cap is less than US$10m (€2.73m market cap, or US$3.19m).
Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).
お知らせ • Aug 28Aptahem AB (publ) Announces Submission of Application for FDA's Commissioner's National Priority Voucher Pilot ProgramAptahem AB (publ) announced that the company has submitted an application for participation in the U.S. Food and Drug Administration's (FDA) Commissioner's National Priority Voucher (CNPV) Pilot Program - "Accelerated Drug Review for Companies Supporting U.S. National Interests." The application is made as a next step after Aptahem's previous application to FDA PreCheck on August 13, 2025. It complements the company's application to FDA PreCheck and strengthens the U.S.-focused regulatory strategy. CNPV is a new pilot program where the FDA, for a limited number of companies, can award a "voucher" that provides significantly shortened regulatory review processing times - from normally around 10-12 months to around 1-2 months - while maintaining applicable safety and efficacy requirements. The selection is directed at development programs that are in line with US national health priorities (e.g., high unmet medical needs, innovation level, crisis management, onshoring, and supply chain robustness). In the first round of the pilot year, a maximum of five participants are intended to be selected. To qualify, it is required, among other things, that the manufacturing part and proposed labeling are submitted at least 60 days before the final application and that the company can maintain a close dialogue with the FDA's cross-functional review team.
お知らせ • Aug 21Aptahem Files Provisional Patent Application in Usa for New Indications for Apta-1Aptahem AB (publ) announced that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1. These new insights are based on the detailed evaluation of data generated from Apta-1 by the Company's Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified entirely new indications for the Company's lead RNA aptamer, Apta-1. These discoveries are now protected by a provisional patent application in the United States, further strengthening Apta-1's position as a first-in-class, innovative therapy option. Some of the identified indications include: Neurodegenerative diseases: Apta-1 blocks interactions of Amyloid-b and tau, with the potential to slow progression in Alzheimer's, Parkinson's, frontotemporal dementia, and Huntington's disease. Viral infections: Effective against HSV, CMV, Dengue, Zika, SARS-CoV-2, MERS, HIV, and HPV by preventing viral cell entry. Cancer and metastasis: Inhibits growth factors, slowing angiogenesis and tumor cell spread in aggressive cancers such as breast cancer, melanoma, and glioblastoma. Fibrotic diseases and infectious conditions: interesting indications for idiopathic pulmonary fibrosis, liver and kidney fibrosis, as well as in certain infectious diseases. Dr. Jedlina's evaluation of the study results shows that Apta-1 has the potential to stop disease-driving mechanisms at multiple levels - from protein aggregation and pathogen entry to tissue damage and fibrosis - making Apta-1 a potential game-changer in these indication areas.
お知らせ • Aug 16Aptahem AB (publ) Applies to FDA Precheck Program - Strategic Step Toward Faster, Higher-Quality Drug ManufacturingAptahem AB (publ) is strengthening its position as a leader in RNA-based therapeutics by applying to the FDA PreCheck Program, the agency's new initiative to accelerate and streamline inspections of drug manufacturing. The program is reserved for companies with a proven track record of high-quality, GMP-compliant operations, offering prioritized inspections and regulatory transparency. For Aptahem, participation means:Faster regulatory pathway for production of Apta-1, its breakthrough RNA aptamer for severe inflammatory conditions. Enhanced confidence from partners and investors, demonstrating the company's commitment to top-tier quality and innovation. Clear quality milestone reducing risks and timelines, supporting future clinical and commercial expansion.
お知らせ • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025
Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).
お知らせ • May 08Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Mar 14Aptahem AB (publ) Presents Plan for Upcoming Patient StudyAptahem AB (publ) announced a summary for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed as an open, single arm phase 2 study to evaluate the efficacy and safety of Apta-1, an innovative immunomodulatory and antithrombotic drug candidate, in patients with acute urogenital andrenal conditions. The study will be perform as a Proof-of-Concept study in adult patients diagnosed with various types of acute urogenital disorders including acute kidney disorders. Within these disorders, there are several indications with orphan status, an area where Aptahem sees great potential for Apta-1 based on its unique therapeutic profile. To maximize the opportunities to create value from Apta-1's broad treatment potential, the study is planned to be conducted as a "basket trial", where several acute medical conditions within the relevant patient group are investigated in parallel. The study's primary objectives include biomarkers for hematology, organ function, inflammation, tissue degradation, and reduction of pathogens such as viruses and bacteria. The goal is to demonstrate both therapeutic efficacy and safety. More detailed information about the study will be published in the near future.
Reported Earnings • Feb 20Full year 2024 earnings released: kr0.69 loss per share (vs kr5.79 loss in FY 2023)Full year 2024 results: kr0.69 loss per share (improved from kr5.79 loss in FY 2023). Net loss: kr8.57m (loss narrowed 23% from FY 2023).
お知らせ • Feb 18+ 1 more updateAptahem AB (publ) to Report Q1, 2025 Results on May 28, 2025Aptahem AB (publ) announced that they will report Q1, 2025 results on May 28, 2025
お知らせ • Jan 16Aptahem AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025Aptahem AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Dec 03Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.18m (loss narrowed 26% from 3Q 2023).
Board Change • Dec 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 31Aptahem AB (publ) to Report Q3, 2024 Results on Nov 29, 2024Aptahem AB (publ) announced that they will report Q3, 2024 results on Nov 29, 2024
お知らせ • Sep 02Aptahem AB (Publ) Announces Completion of Double-Blind Randomised Placebo-Controlled Phase 1 StudyAptahem AB (publ) announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. The analyses revealed that one individual had elevated inflammatory values prior to dosing. In this case, Apta-1 dosing was associated with rapid reduction of inflammatory parameters, with the first signs of normalisation seen already within 4 hours of dosing and further reduction at 6 hours to be completely reduced at the next measurement point at 24 hours. This suggests that Apta-1 could counteract inflammatory responses in individuals with ongoing inflammation. The latter observations are consistent with preclinical data and the proposed mechanism of action showing that Apta-1 protects against acute inflammation. This has been replicated in several independent models and reinforces the belief that Apta-1 can be developed into an effective drug against life-threatening inflammatory disease. Strengthened by these findings, a confirmatory Phase 2 clinical trial in patients with acute inflammatory disease is now being planned in consultation with the company's expert advisors.
Reported Earnings • Sep 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr2.63m (loss narrowed 3.7% from 2Q 2023).
お知らせ • Aug 01Aptahem AB (publ) to Report Q2, 2024 Results on Aug 30, 2024Aptahem AB (publ) announced that they will report Q2, 2024 results on Aug 30, 2024
Board Change • Jul 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 28Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been FinalizedAptahem AB (publ) announced that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities. The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study of Apta-1 highlighted some clinical markers which are important for understanding the mechanism of action and to support upcoming patient studies. The significance of these findings are being further investigated aided by pre-clinical studies.
Board Change • Jun 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Jan Nilsson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.